Editing Type:
Enzyme:
Editing Level:
Correlation:
Gene Symbol Aliases Editing Sites Enzyme Editing Type Molecular Consequence Editing Level Correlation Phenotype Disease
CTSS - 41 ADAR1 A-to-I mRNA stability change Present Negative Reduce atherosclerosis and angiogenesis
AZIN1 - 2 ADAR1;ADAR2 A-to-I Nonsynonymous substitution Present Positive Promote tumor cellular proliferation;Promote aggressive behaviors in tumor progression
FLNB - 1 ADAR1;ADAR2 A-to-I Nonsynonymous substitution Increased Positive Increase RNA editing level in disease; Induce malignant phenotypes during tumor progression
COPA - 1 ADAR1;ADAR2 A-to-I Nonsynonymous substitution Increased Positive Affect tumor pathogenesis
IGFBP7 - 3 ADAR1;ADAR2 A-to-I Nonsynonymous substitution Decreased Positive Inhibit tumor cell apoptosis; Reduce RNA editing event promote tumor cell proliferation
GRIA2 GLUR2 1 ADAR2 A-to-I Nonsynonymous substitution Decreased Negative Reduce RNA editing in disease
GRIA3 GLUR3 1 ADAR2 A-to-I Nonsynonymous substitution Decreased Negative Promote recovery of spinal core injury
GRIA4 GLUR4 1 ADAR2 A-to-I Nonsynonymous substitution Decreased Negative Promote recovery of spinal core injury
GRIK1 GLUR5 1 ADAR2 A-to-I Nonsynonymous substitution Decreased Negative Reduce RNA editing in disease
GRIK2 GLUR6 1 ADAR2 A-to-I Nonsynonymous substitution Decreased Negative Reduce RNA editing in disease
HTR2C - 6 ADAR1;ADAR2 A-to-I Nonsynonymous substitution Present Positive Induce disease
RHOQ - 1 NA A-to-I Nonsynonymous substitution Increased Positive Promote recurrence
PINK1 - 1 ADAR2 A-to-I Nonsynonymous substitution Present Negative Repair mitophagy
EDNRB ETB 1 ADAR1;ADAR2 A-to-I Nonsynonymous substitution Present Positive Induce disease
BLCAP - 12 ADAR1;ADAR2 A-to-I Nonsynonymous substitution; mRNA expression change Decreased Negative Reduce RNA editing in disease
SLC1A2 EAAT2 1 ADAR1;ADAR2 A-to-I Alternative splicing Present Positive Affect disease processing
PTPN6 - 1 NA A-to-I Alternative splicing Present Positive Affect disease processing
LDLR - 1 NA G-to-C Alternative splicing Present Positive Reduce hypercholesterolemia
CDC14B - 13 ADAR2 A-to-I - Decreased Negative Reduce RNA editing in disease
TPH2 - 5 APOBEC A-to-I; G-to-A; C-to-U Alternative splicing Present Positive Affect disease processing
HNRNPK - 1 APOBEC3B G-to-A Nonsynonymous substitution Present Positive Affect disease processing
PODXL - 1 ADAR1;ADAR2 A-to-I Nonsynonymous substitution Absent Positive Reduce tumorigenic ability
GLI1 - 1 ADAR1 A-to-I Nonsynonymous substitution Present Positive Increase RNA editing level in disease
NF1 - 1 NA C-to-U Nonsynonymous substitution Increased Positive Increase RNA editing level in disease
ARPIN - 2 ADAR1;ADAR2;ADAR3 A-to-I - Present Positive Promote the disease risk
DHFR - 25 ADAR1 G-to-A mRNA expression change Increased Positive Promote tumor cell proliferation
NEIL1 - 1 ADAR1 A-to-I Nonsynonymous substitution Increased Positive Increase RNA editing level in disease
WT1 - 1 APOBEC3A G-to-A Nonsynonymous substitution Present Positive Induce mutation of wilms tumor and acute myeloid leukemia
GABRA-3 - 1 ADAR1;ADAR2 G-to-A Nonsynonymous substitution Present Positive Affect the variability GABAA receptors in sensitivity to drugs
SLC22A3 - 1 ADAR2 A-to-I Nonsynonymous substitution Present Positive Promote the tumor progression and malignant development
FLNA - 1 ADAR1;ADAR2 NA Nonsynonymous substitution Decreased Negative Exacerbation the psoriasis
CDK13 - 2 ADAR1 A-to-I Nonsynonymous substitution Increased Positive Affect HCC tumor tissues and associated with poor prognosis
Editing Type:
Enzyme:
Editing Level:
Correlation:
miRNA ID Editing Sites Enzyme Editing Type Molecular Consequence Editing-Level Target Change Correlation Phenotype Disease
hsa-mir-214 2 ADAR2 U-to-C miRNA and its target gene expression change Increased
  • Rab15->Rab15
- Occur in tumor
hsa-mir-122 1 ADAR2 A-to-I miRNA and its target gene expression change Increased - - Occur in tumor
hsa-miR-200b 1 ADAR1;ADAR2 A-to-I - Increased
  • TP53->TP53
  • BRAF->BRAF
  • NRAS->NRAS
  • CDH1->CDH1
  • ZEB1->ZEB1
  • ZEB2->ZEB2
  • LIFR->LIFR
- Inhibit survival capability
hsa-miR-99a 1 ADAR1;ADAR3 A-to-I - Increased
  • TP53->TP53
  • PIK3CA->PIK3CA
  • MAP3K1->MAP3K1
  • HRAS->HRAS
  • NRAS->NRAS
Positive Affect disease
hsa-miR-376a 1 ADAR1 A-to-I Retargeting of miRNA Increased
  • RAP2A->AMFR
Positive Promote tumor migration and invasion
hsa-miR-455-5p 2 ADAR1 A-to-I Target gene expression change Absent
  • CPEB1->CPEB1
Negative Inhibit tumor growth and metastasis
hsa-let-7a-1 2 ADAR1 A-to-I Regulate miRNA biogenesis Increased - Negative Promote survival capability
hsa-miR-132-3p 2 - A-to-I miRNA expression change Increased - Positive Affect disease
hsa-mir-27b 1 - A-to-I - Increased - Positive Promote plasma levels of high-density lipoprotein
hsa-miR-605 1 - A-to-I - Increased - Positive Promote plasma levels of high-density lipoprotein
hsa-miR-378a-3p 1 ADAR1 A-to-I Target gene expression change Increased
  • PARVA->PARVA
Positive Inhibit tumor progression
hsa-miR-589-3p 3 ADAR2 A-to-I Retargeting of miRNA Increased
  • PCDH9->ADAM12
Negative Inhibit tumor proliferation, migration and invasion
hsa-miR-221 2 ADAR2 A-to-I miRNA expression change Increased - Positive Affect tumor migration and invasion
hsa-miR-222 2 ADAR2 A-to-I miRNA expression change Increased - Positive Affect tumor migration and invasion
hsa-miR-381 2 ADAR2 A-to-I miRNA expression change Increased - Positive Affect tumor migration and invasion
hsa-miR-142-3p 1 ADAR2 U-to-C miRNA expression change Increased - Positive Affect cell migration and proliferation
lncRNA name Editing site(s) Enzyme Editing Type Editing-Level Target Correlation Phenotype Disease
PCA3 1 ADAR1;ADAR2 A-to-I Present PRUNE2 Positive Promote prostate cancer malignant cell growth